About Fusion Antibodies
Fusion Antibodies is a company based in Belfast (United Kingdom) founded in 2001. Fusion Antibodies has raised $2.5 million across 4 funding rounds from investors including Invest Northern Ireland, Crescent Capital and Qubis. Fusion Antibodies offers products and services including Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development. Fusion Antibodies operates in a competitive market with competitors including SSI Strategy, August Research, ProductLife Group, Health Decisions and Phastar, among others.
- Headquarter Belfast, United Kingdom
- Stage Public
- SectorsHealthcare
- Website fusionantibodies.com
- Social LinkedIn X Facebook
- Legal Name Fusion Antibodies Plc
- Annual Revenue$2.79 M (USD)7.38as on Mar 31, 2026
- Net Profit-$1.52 M (USD)29.34as on Mar 31, 2026
- EBITDA-$2.45 M (USD)-14.37as on Mar 31, 2026
- Total Equity Funding$2.5M (USD)
in 4 rounds
- Latest Funding Round$1.77M (USD), Post-IPO
Feb 2024
- InvestorsInvest Northern Ireland
& 3 more
Products & Services of Fusion Antibodies
Fusion Antibodies offers a comprehensive portfolio of products and services, including Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development.
Service for humanizing antibodies to reduce immunogenicity for therapeutics.
Process to reformat antibodies for improved functionality and production.
Technique to enhance antibody binding affinity for better efficacy.
Creation of stable cell lines for antibody production and testing.
Funding Insights of Fusion Antibodies
Fusion Antibodies has successfully raised a total of $2.5M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.77 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.5M
- Total Rounds 4
- Last Round Post-IPO — $1.77M
- First Round $2.5M
(Jul 2007)
- Investors Count 4
All 4 funding rounds of Fusion Antibodies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $1.77M | Post-IPO | – | – | – |
| Oct 2020 | $244,882 | Grant | – | – | |
| Mar 2018 | $21,383 | Grant | – | – | |
| Jul 2007 | $2.5M | Private Equity Round | – | – |
4 investors in total: 4 institutional.
Investors in Fusion Antibodies
Fusion Antibodies has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Invest Northern Ireland, Crescent Capital and Qubis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | crescentcapital.co.uk | - | |
Qubis is engaged in commercializing academic research from Queen's University. | – | qubis.co.uk | Belfast, United Kingdom | |
- | – | viridianinvestmentpartners.com | - | |
Business support and investment attraction services are provided to enterprises. | 2002 | investni.com | Belfast, United Kingdom |
Investor details for Fusion Antibodies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Fusion Antibodies
8 people are tracked at Fusion Antibodies (5 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Adrian Kinkaid | CEO | Leadership |
Nicola Hamilton | Director Of Operations | Leadership |
Dr Adrian Kinkaid | Chief Executive Officer | Leadership |
Richard Buick | Chief Scientific Officer | Leadership |
Simon Asbjørn Larsen | Collaborative Research Director | Leadership |
Christopher King | Business Development Services Manager | Team |
Richard | Collaboration Manager | Team |
Julie Garvin | Facilities Manager | Team |
Complete people profiles for Fusion Antibodies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Fusion Antibodies
Fusion Antibodies is a publicly listed company on the LSE with ticker symbol FAB in UK, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Dec 2017
- Listed onLSE: FAB
- Listed entityFusion Antibodies Plc
- Exchange sectorHealth services
- ISINGB00BDQZGK16
- Share price10.50 GBX (+5% on the day) · 2026-10-09
- Market capitalisation12,515,688.00 GBX
- EPS (diluted, trailing year)-0.01 GBX
- Volume (last session)836
Financials of Fusion Antibodies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.1M GBP | -1.1M GBP | -1.9M GBP |
| 2024 | 2.0M GBP | -1.6M GBP | -1.6M GBP |
| 2023 | 1.1M GBP | -2.2M GBP | -2.1M GBP |
| 2022 | 2.9M GBP | -2.6M GBP | -2.5M GBP |
| 2021 | 4.8M GBP | -1.2M GBP | -581,000 GBP |
Detailed financial statements for Fusion Antibodies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Fusion Antibodies
4 dated milestones of Fusion Antibodies across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Fusion Antibodies is founded.
- Funding First funding round of $2.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $1.8M.
Competitors of Fusion Antibodies
Fusion Antibodies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SSI Strategy, August Research, ProductLife Group, Health Decisions and Phastar, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ssistrategy.com | 2010 | Parsippany Troy Hills, United States | – | – | Pharmacovigilance and medical affairs services are offered for drug development. | |
| augustresearch.com | 2012 | Sofia, Bulgaria | – | – | Clinical trial services are offered in Central and Eastern Europe. | |
| productlifegroup.com | 2000 | Suresnes, France | – | – | Regulatory and pharmacovigilance support is provided for product lifecycles. | |
| healthdec.com | 1989 | Durham, United States | $1.8M | 110 | CRO focused on clinical trial services for data management, monitoring and biostatistics | |
| phastar.com | 2007 | London, United Kingdom | – | – | Statistical consulting and data management for clinical trials are offered. | |
| ecrscorp.com | 2004 | Markham, Canada | – | – | Full-service clinical research services are provided to life science industries. | |
| cromsource.com | 1994 | Verona, Italy | – | 32 | An ISO-certified CRO and provider of outsourced services to the pharmaceutical, biotechnology and medical device industries |
Detailed competitors of Fusion Antibodies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Fusion Antibodies
Websites that share an audience with Fusion Antibodies (fusionantibodies.com).
Websites whose visitors overlap most with Fusion Antibodies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| randox-lifesciences.com | 100% | – | – | View details | |
| abnova.com | 100% | 30.7K | #957,320 | View details | |
| ptglab.com | 100% | – | #137,673 | View details | |
| abgent.com | 100% | – | – | View details | |
| epitomics.com | 99% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for Fusion Antibodies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Fusion Antibodies
Complete news archive for Fusion Antibodies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Fusion Antibodies
10 companies that operate in the same segment as Fusion Antibodies (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Fusion Antibodies
Fusion Antibodies was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Fusion Antibodies is headquartered in Belfast, United Kingdom. It is registered at Belfast, Northern Ireland, United Kingdom.
Adrian Kinkaid is the current CEO of Fusion Antibodies.
Fusion Antibodies is a funded company, having raised a total of $2.5M across 4 funding rounds to date. The company's 1st funding round was a Private Equity Round of $2.5M, raised on Jul 2007.
Annual revenue of Fusion Antibodies is $2.79M as on Mar 31, 2026.
Founded in 2001 and based in Belfast, United Kingdom, Fusion Antibodies operates as a contract research organization in the biotechnology sector. Services encompass antibody sequencing, humanization, stable cell line development, engineering, monoclonal antibody production, and transient protein expression. Two proprietary antibodies are currently in clinical and preclinical trials, supporting drug discovery and development processes.
Fusion Antibodies's top competitors include SSI Strategy, ProductLife Group and Health Decisions.
Fusion Antibodies offers Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development.
Yes, Fusion Antibodies is publicly traded on LSE under the ticker symbol FAB.
Fusion Antibodies has 4 investors. Key investors include Invest Northern Ireland, Crescent Capital, Qubis, and Viridian Investment Partners.
Fusion Antibodies operates through Fusion Antibodies Plc.